Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice

• Үндсэн зохиолчид: Alistair Ring (Зохиогч), Meghan Karuturi (Зохиогч), Emily Nash Smyth (Зохиогч), Tasneem Lokhandwala (Зохиогч), Kristin M. Sheffield (Зохиогч), Joanne Willey (Зохиогч), Orsolya Lunacsek (Зохиогч), Francisco Sapunar (Зохиогч), Zhanglin Lin Cui (Зохиогч), Anna D. Coutinho (Зохиогч), Sarah Rybowski (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Adis, Springer Healthcare, 2023-09-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Abstract Introduction Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) is the most frequently diagnosed metastatic breast cancer (mBC) subtype. Combinations of endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitors (CDK4 & 6is) improve outcome...